Sponsors (4)
The bill provides predictable, dedicated funding and clearer standards that should speed and stabilize OTC drug oversight and reduce regulatory friction, but it raises fees (shifting costs to businesses and consumers), concentrates discretion, and risks reduced flexibility, transparency, and some statutory protections.
Patients and consumers will likely see faster, more consistent OTC monograph reviews and improved access to safe over-the-counter medicines because the bill dedicates and stabilizes fee funding for OTC monograph activities.
Manufacturers, small businesses, and FDA will benefit from predictable, transparent fee schedules and fixed dollar adjustments (with published fees at least 60 days before each fiscal year), improving budgeting and regulatory planning.
Drug manufacturers can rely on recognized voluntary consensus testing standards and an explicit administrative pathway to adopt those standards, reducing regulatory uncertainty and potentially improving product testing consistency.
Manufacturers, fee payers, and ultimately taxpayers/consumers will face higher costs because the bill authorizes new and increased fees (including specified add-ons and potential one-time increases tied to facility growth), which may be passed through as higher product prices.
Existing statutory protections, reporting requirements, and program authorities (e.g., sections 744L/744M and the section 744N report) will expire or be eliminated, reducing regulatory safeguards, oversight data, and transparency that hospitals, states, and the public rely on.
Dedicating fees narrowly to OTC monograph activities and tying recognition rules to specific guidance concentrates fiscal and administrative discretion, which could reduce FDA flexibility to reallocate funds during shortages/emergencies and concentrate decisionmaking authority.
Based on analysis of 8 sections of legislative text.
Introduced July 15, 2025 by James E. Banks · Last progress July 15, 2025
Establishes a revised user-fee framework for the FDA’s over-the-counter (OTC) monograph drug program for fiscal years 2026–2030, including how facility and order-request fees are timed, calculated, and adjusted. It also adds a narrow exception recognizing voluntary consensus testing standards, updates annual reporting language, sets expiration dates for the program provisions, and fixes the effective date and transition rules. The law requires the FDA to publish fee amounts at least 60 days before each fiscal year, creates limited one-time revenue add-ons and a possible workload-based facility-fee adjustment, preserves prior law for fees collected before FY2026, and sunsets the statutory fee authorities in 2030–2031 unless renewed earlier.